Reported Sunday, Ivonescimab Monotherapy Reduces Risk Of Death By 27% Versus Pembrolizumab In PD-L1-Positive Advanced NSCLC, Akeso's HARMONi-2 Study Shows

뉴스 본문을 불러오고 있어요.

Reported Sunday, Ivonescimab Monotherapy Reduces Risk Of Death By 27% Versus Pembrolizumab In PD-L1-Positive Advanced NSCLC, Akeso's HARMONi-2 Study Shows | 웨이프 WAPE

Reported Sunday, Ivonescimab Monotherapy Reduces Risk Of Death By 27% Versus Pembrolizumab In PD-L1-Positive Advanced NSCLC, Akeso's HARMONi-2 Study Shows

기사 요약

관련 종목

댓글 —